We will be focusing on the uses of anti-angiogenic agents, epidermal growth factor receptor (EGFR) inhibitors, HER2/neu antibodies, and phosphoinositide 3-kinase (PI3K)-PTEN-AKT-mammalian target of rapamycin (mTOR) pathway inhibitors in endometrial cancer (seeTable 1). The gene discussed is ERBB2; the disease is endometrial cancer.